bluebird bio Past Earnings Performance

Past criteria checks 0/6

bluebird bio has been growing earnings at an average annual rate of 26.8%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 9.2% per year.

Key information

26.8%

Earnings growth rate

40.6%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-9.2%
Return on equityn/a
Net Margin-551.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing Enough For Some Investors

Nov 15
bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing Enough For Some Investors

bluebird bio: Scientific Success And Financial Success, And The Gap Between

Sep 26

bluebird bio's Flight Through Financial Fog And Fierce Rivals

Jun 27

bluebird bio Is Priced Below IP Value

Mar 23

Bluebird Bio: Innovative Therapies, Monetary Setbacks

Jan 25

Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?

Oct 13
Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?

Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation

Jul 13
Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation

Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo

Oct 04

Bluebird bio names interim finance chief

Sep 26

Bluebird bio jumps 17% on FDA approval of new gene therapy

Sep 19

bluebird bio' chief strategy and financial officer to depart

Sep 12

FDA approves bluebird bio's Zyntego beti-cel gene therapy for beta thalassemia

Aug 17

bluebird bio: Potential For 3 Gene Therapy Approvals In 12 Months Makes Buy Case

Jun 22

bluebird bio: Beaten Down Biotech With Possible Long-Term Potential

May 09

Revenue & Expenses Breakdown

How bluebird bio makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:BLUE Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2453-29320588
30 Jun 2455-319207122
31 Mar 2446-301198128
31 Dec 2329-212190143
30 Sep 2322-63202283
30 Jun 239-52172106
31 Mar 234-89170136
31 Dec 224-230169171
30 Sep 225-4311590
30 Jun 226-507180125
31 Mar 225-56319070
31 Dec 214-5632100
30 Sep 21-238-5731870
30 Jun 21-220-6142170
31 Mar 21-21-4802300
31 Dec 200-5612400
30 Sep 20250-6422860
30 Jun 20240-6532840
31 Mar 2054-8282840
31 Dec 190-5552360
30 Sep 1954-7152490
30 Jun 1957-6552270
31 Mar 1951-6051990
31 Dec 1855-5561740
30 Sep 1840-5241500
30 Jun 1836-4571280
31 Mar 1845-3821080
31 Dec 1735-336940
30 Sep 1733-290810
30 Jun 1727-288720
31 Mar 1711-276690
31 Dec 166-264650
30 Sep 166-239630
30 Jun 166-205620
31 Mar 169-198550
31 Dec 1514-167460
30 Sep 1519-139360
30 Jun 1524-113290
31 Mar 1525-63240
31 Dec 1425-49230
30 Sep 1425-37230
30 Jun 1425-26200
31 Mar 1425-29170
31 Dec 1320-25140

Quality Earnings: BLUE is currently unprofitable.

Growing Profit Margin: BLUE is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BLUE is unprofitable, but has reduced losses over the past 5 years at a rate of 26.8% per year.

Accelerating Growth: Unable to compare BLUE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BLUE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: BLUE's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 00:12
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

bluebird bio, Inc. is covered by 34 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Huidong WangBarclays
Zhiqiang ShuBerenberg